The Effect of Concentrated Pomegranate Juice Consumption on Lipid Profile and Inflammatory Factors in Patients With Type 2 Diabetes

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02024516

Enrollment

Unknown

Registered

2013-12-31

Start date

2013-01-31

Completion date

Unknown

Last updated

2013-12-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Keywords

Type 2 diabetes, Pomegranate, Inflammation, lipid profiles

Brief summary

The aim of this study is to examine the effects of concentrated pomegranate juice on serum lipid profile and some inflammatory factors in patients with type 2 diabetes. Forty patients aged between 25-60 years old from both sexes are recruited. Patients consume 50gr/day concentrated pomegranate juice for 4 weeks. Anthropometric and blood pressure measurements, 3-days food-record questionnaire ,physical activity and fasting blood samples were collected at the beginning and at the end of the study. Fasting blood sugar, lipid profile, TNF- a, IL-6,hs -CRP and adiponectin levels are measured. LDL are calculated by formula. The participants are asked not to change their regular diet, medicine and activity during the study.

Interventions

OTHER50 gr concentrated pomegranate juice

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

25 Years to 60 Years

Inclusion criteria

* male or female 25 to 60 years old * having type 2 diabetes for at least 6 month

Exclusion criteria

* pregnancy * lactation * cardiac disease * hepatic disease * respiratory disease * chronic renal diseases * acute or chronic inflammation * retinopathy * intake of antioxidant supplement * insulin therapy * sensitivity to concentrated pomegranate juice * change oral drug for controlling blood glucose

Design outcomes

Primary

Measure	Time frame
adiponectin change	Baseline and after 4 weeks
hsCRP change	Baseline and after 4 weeks
TNF- α change	Baseline and after 4 weeks
IL-6 change	Baseline and after 4 weeks
Triglyceride change	Baseline and after 4 weeks
Total Cholesterol change	Baseline and after 4 weeks
HDL- Cholesterol change	Baseline and after 4 weeks
LDL- Cholesterol change	Baseline and after 4 weeks

Secondary

Measure	Time frame
Blood Pressure change	Baseline and after 4 weeks
Body Mass Index change	baseline and after 4 weeks
Fasting Blood Sugar change	baseline and after 4 weeks

Countries

Iran

Contacts

Primary ContactMaryam Zare, MS condidate

zare.m@ajums.ac.ir+989132275832

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026